Although the increased serum level of PSA in prostate cancer patients is commonly considered to be due to disruption of prostate architecture associated with, for example, cancer, the exact molecular mechanism by which serum level of PSA is increased in prostate cancer patients is still unclear as experimental models and data are currently lacking [15, 16]. This evidence concerns the gene KLK3 and cancer.